ReNerve (ASX:RNV), an Australian biotechnology firm specialising in peripheral nerve injury repair, has transitioned its flagship NervAlign Nerve Guide Matrix into Stage 3 of its four-stage commercial production scale-up.
The pivotal phase serves as the verification bridge necessary for formal submission to the United States Food and Drug Administration.
Stage 3 focuses on the rigorous verification of the development process. During this period, the company will manufacture the specific product batches required for the commencement of formal preclinical testing.
Additionally, this stage involves the production of final consumer packaging and the refinement of large-scale manufacturing protocols.
ReNerve anticipates completing this phase by the conclusion of the 2026 calendar year, maintaining a steady trajectory towards global market entry.
Dr Julian Chick, CEO of ReNerve, emphasised the strategic importance of this milestone, noting that large animal model testing has already demonstrated the Matrix's efficacy in replacing damaged nerves.
"This product offers surgeons a vital alternative to donor nerves, which often come with significant biological limitations," Dr Chick stated.
The NervAlign Nerve Guide Matrix is being developed within a Good Manufacturing Practice certified facility to ensure the highest regulatory standards are met.
As ReNerve advances, the company remains in active consultation with the FDA, incorporating direct feedback into the final Stage 4 production and testing protocols.
At the time of reporting, ReNerve's share price was $0.10.